Double Dose Magnesium Sulphate in Moderate-severe Asthma in Paediatrics
Status:
Not yet recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
Introduction : . In Oman the prevalence of asthma was estimated to be 7.3% of adults and
12.7% of children . Magnesium sulphate is the second line treatment, many studies had shown
that it has beneficial effect in treating acute asthma in children ; it reduces the hospital
stay and the rate of admission as well as the ventilation rate .
Aim : To compare single dose Magnesium sulphate that is typically given in the emergency
department verses two doses of magnesium sulphate in treating acute moderate-severe asthma
exacerbation in paediatric age group Research hypothesis : Children who are treated with two
doses MgSO4 are more likely to have improvement in their PRAM score and are less likely to be
admitted to the ward, HD or ICU Primary outcome : Improvement in PRAM (Paediatric respiratory
assessment measure) score of acute asthma exacerbation Secondary outcome : Reduce admission
rate to general ward, PICU and HD . Demonstrate the safety profile of double dose of
magnesium sulphate.
Study Design : prospective blinded randomized trial
Study population : children age 3-13 years who presented to Royal hospital paediatric
emergency with moderate-severe acute asthma
Intervention : two doses magnesium sulphate
Comparison : Placebo
Outcome : Improvement in PRAM score